Skip to main content
This content is intended for customers outside the US. Click the link for specific information for the USA.
Go to the USA content
Home Novosanis
Menu
  • About us
  • Products
  • Home collection
  • Dataroom
    • White Papers
    • Posters
    • Publications
    • Brochures & Flyers
    • Instructions for use
    • Datasheets
  • News & Events
  • Contact
  • Careers
  • FAQs
  • International
  • USA

Posters

You are here

Home » Dataroom » Posters
Reset filters

Year

  • 2022 (2) Apply 2022 filter
  • (-) Remove 2021 filter 2021
  • 2019 (2) Apply 2019 filter
  • 2017 (2) Apply 2017 filter
  • 2016 (2) Apply 2016 filter

Event

  • (-) Remove ACTC filter ACTC
  • (-) Remove EUROGIN filter EUROGIN
  • IPVC (2) Apply IPVC filter
  • ISLB (3) Apply ISLB filter

Application area

  • (-) Remove Device filter Device
  • Infectious diseases (3) Apply Infectious diseases filter
    • HPV (3) Apply HPV filter
  • (-) Remove Oncology filter Oncology
    • (-) Remove Cervical cancer filter Cervical cancer

Author

  • Michelle Laeremans (1) Apply Michelle Laeremans filter
  • Stephanie Jordaens (1) Apply Stephanie Jordaens filter

Dataroom

cfDNA isolation from first-void urine using the Colli-Pee device containing UAS (ACTC 2021)

29/09/2021
ACTC - Jordaens et al., 2021.

Feedback from a colposcopy referral population on the use of Colli-Pee for HPV-based cervical cancer screening (CASUS) (EUROGIN 2021)

10/06/2021
Eurogin - Laeremans et al., 2021.

Products

  • Colli-Pee
  • Home collection
  • Regulatory
  • Frequently Asked Questions

Communication

  • News
  • Infographics
  • Blogs
  • Press releases
  • Events
  • Podcasts & Webinars

Dataroom

  • White Papers
  • Posters
  • Publications
  • Brochures & Flyers
  • Instructions for use
  • Datasheets

Connect with us

Facebook
Instagram
Linkedin
Youtube
Twitter
Slideshare

Contact

Bijkhoevelaan 32c
2110 Wijnegem
Belgium
+32 3 485 50 16
welcome@novosanis.com

Disclaimer

Novosanis is a wholly owned subsidiary of OraSure Technologies, Inc. (NASDAQ: OSUR), and an innovative developer and producer of medical devices improving the quality of diagnostic tests for infectious diseases and oncology. The Colli-Pee® family, the heart of the company, allows volumetric and standardized collection of first-void urine. The platform consists of variants capturing a range of urine volumes for different application purposes. Urine collection through the Colli-Pee® device is easy, comfortable, and more accurate than a regular urine cup. First-void urine has shown to improve detection of infectious diseases, including sexually transmitted infections as well as for some cancers applications. The Colli-Pee® device enables immediate mixing of the first-void urine sample with a preservative, improving stability of the urine specimen. Novosanis markets its products worldwide and has a global customer base.

2022 © Novosanis, a subsidiary of OraSure Technologies, Inc., all rights reserved.

2022 © Novosanis

  • Cookie policy
  • Privacy Policy
  • Disclaimer
  • Terms & conditions
  • Quality policy

Drupal website by Dropsolid